Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$10.33M, compared with -$6.8M a year earlier. Trailing-twelve-month operating income was -$41.17M.
Context
- Operating income amounted to 754.1% of revenue in FY2025, down 2491.1 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -$23.29M (+23.8%) for the fiscal year ending Dec 2026, a slowdown from the +49.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.33M-3.8% QoQ
- Last fiscal yearDec 2025
- -$30.58M+49.9% YoY
- LTMMar 2026
- -$41.17M+29.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -51.9% | +5.1% | +57.0 pp |
| 1 year | +49.9% | +23.8% | -26.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (30.58M) USD
- Year-over-year change
- +49.9%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.58M) | +49.9% |
| FY2024 | 2024-12-31 | (61.04M) | -142.8% |
| FY2023 | 2023-12-31 | (25.14M) | -39.7% |
| FY2022 | 2022-12-31 | (18M) | +66.5% |
| FY2021 | 2021-12-31 | (53.73M) | — |
Operating Income vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 operating income of -$41.17M is the 3rd highest of the 10 companies compared; the peer median is -$81.23M.
- Its year-over-year change of +29.7% is the 4th highest of 10, against a peer median of +18.2%.
- Operating income amounts to 2112.4% of revenue for IMDX, versus a peer median of 322.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$25.89M | +61.4% | — | 33.2% | |
| LTM Mar 2026 | -$37.23M | +7.9% | — | 1258.6% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$41.17M | +29.7% | — | 2112.4% |
| LTM Mar 2026 | -$57.93M | +18.2% | — | 200.3% | |
| LTM Mar 2026 | -$65.46M | -25.5% | — | 3669.4% | |
| LTM Mar 2026 | -$81.23M | +25.7% | — | — | |
| LTM Mar 2026 | -$81.77M | +44.6% | — | 146.4% | |
| LTM Mar 2026 | -$84.14M | +39.9% | — | 503.2% | |
| LTM Mar 2026 | -$110.32M | -34.4% | — | 319.2% | |
| LTM Mar 2026 | -$113.84M | +2.3% | — | 326.6% | |
| Peer median (excluding IMDX) | -$81.23M | +18.2% | — | 322.9% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.2M | 958K | 1.5M | 1.88M | 4.06M |
| Cost of Revenue | 778K | 976K | 1.09M | 1.14M | 3.87M |
| Gross Profit | 1.42M | (18K) | 413K | 740K | 190K |
| Gross Margin | 64.6% | -1.9% | 27.5% | 39.3% | 4.7% |
| Research & Development | 5.04M | 7.3M | 9.29M | 9.84M | 15.9M |
| Selling, General & Admin | 20.39M | 21.53M | 13.29M | 13.79M | 16.98M |
| Operating Expenses | 55.15M | 17.98M | 25.55M | 61.78M | 30.77M |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| EBITDA | (48.46M) | (13.31M) | (23.12M) | (59.02M) | (47.92M) |
| EBITDA Margin | -2204.6% | -1389.2% | -1538.5% | -3137.4% | -1181.7% |
| Operating Income | (53.73M) | (18M) | (25.14M) | (61.04M) | (30.58M) |
| Operating Margin | -2444.3% | -1878.6% | -1672.4% | -3245.1% | -754.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 209K | 83K | 52K | 84K | 109K |
| Other Income / Expenses | 854K | (615K) | 281K | 378K | (19.64M) |
| Income Before Tax | (52.87M) | (18.61M) | (24.86M) | (60.66M) | (50.22M) |
| Pre-Tax Margin | -2405.4% | -1942.8% | -1653.7% | -3225.0% | -1238.5% |
| Income Tax Expense | (9.26M) | 0 | 0 | 0 | 0 |
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Net Margin | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (Basic) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| EPS (Diluted) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| Weighted Avg Shares | 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
| Weighted Avg Shares (Diluted) | 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.